Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 93Leukemia 70Lymphoma 52Leukemia, Myeloid, Acute 41Burkitt Lymphoma 36Myelodysplastic Syndromes 32Lymphoma, Non-Hodgkin 27Hodgkin Disease 27Lymphoma, Mantle-Cell 24Leukemia, Lymphocytic, Chronic, B-Cell 23Recurrence 21Lymphoma, Large B-Cell, Diffuse 21Graft vs Host Disease 21Lymphoma, Follicular 19Congenital Abnormalities 18Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Multiple Myeloma 17Leukemia, Myeloid, Accelerated Phase 16Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Myeloproliferative Disorders 15Leukemia, Myelomonocytic, Chronic 15Blast Crisis 15Lymphoma, B-Cell, Marginal Zone 14Leukemia, Myeloid, Chronic-Phase 13Lymphoma, Large-Cell, Immunoblastic 12Hematologic Neoplasms 12Primary Myelofibrosis 11Lymphoma, Large-Cell, Anaplastic 11Breast Neoplasms 11Neoplasms, Plasma Cell 10

Interventions

durvalumab 1Vinblastine 1Methotrexate 1Gemcitabine 1Doxorubicin 1Cystectomy 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Bladder Adenocarcinoma × Methotrexate × Clear all
NCT03912818 2023-09-11

Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer

Stanford University

Phase 2 Terminated
7 enrolled 9 charts
GenitourinarySarcoma

Bladder Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡